NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 1999
Industry: Formulation and production of encapsulated and tablet vitamins, nutrients, and phytochemicals.
Operations: The Company manufactures nutritional supplements for domestic and international clients, providing services such as clinical studies assessment and product formulation. It operates manufacturing facilities in San Marcos and Vista, California, and established a European subsidiary in Switzerland in January 1999.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 15.4% ($10.5 million) due to increased product/price competition and reduced demand for herbal products.
• Margin Compression: Gross margin fell from 27.6% to 21.6%. Cost of goods sold rose to 78.4% of sales, driven by inventory write-downs and liquidation of slow-moving stock at or below cost.
• Operating Loss: The Company swung from a $9.6 million operating profit in 1998 to a $4.9 million operating loss in 1999. This was caused by a $6.3 million drop in gross profit, a $3.2 million increase in SG&A expenses, and a $5.0 million charge related to a lease obligation.
• Lease Impairment: A significant non-cash charge of approximately $5.0 million was recorded regarding a partially completed facility in Carlsbad, California, which the Company decided to sublease rather than occupy. This included a $2.3 million impairment of leasehold assets and a $2.7 million accrual for future lease payments.
• SG&A Increase: Selling, general, and administrative expenses rose to $12.3 million (21.4% of sales) from $9.1 million (13.4% of sales), attributed to Y2K compliance costs, management restructuring, and higher rents for new facilities.

Guidance, Outlook, and Risks

• Outlook: Management expects competition to remain strong. International sales grew 18.8% to $17.7 million, and management anticipates this segment will continue to expand as a percentage of total sales.
• Liquidity: The Company has $3.0 million in available revolving credit lines (currently unutilized) and working capital of $14.1 million. However, management plans to pursue additional financing in fiscal 2000 to meet funding requirements, with no assurance of availability.
• Capital Expenditures: Capital expenditures were $5.7 million in 1999. The Company anticipates spending approximately $5.4 million in fiscal 2000.
• Key Risks:
  • Customer Concentration: Three customers (Nu Skin International, NSA International, and Pharmavite) accounted for 71% of sales in 1999. Loss of any could materially impact the business.
  • Regulatory: Operations are subject to FDA, FTC, and other regulations regarding labeling, safety, and claims. Future regulations could require product reformulation or recalls.
  • Year 2000 Compliance: The Company incurred approximately $1 million in Y2K costs. While systems were upgraded, risks remain regarding supplier compliance.
  • Management Changes: Significant turnover occurred in 1999, including the resignation of the former President/CFO and the appointment of new executives.

Investor Verification Checklist

• Customer Retention: Verify the status of contracts with the top three customers representing 71% of revenue.
• Lease Obligations: Confirm the status of the Carlsbad facility sublease and the accuracy of the $2.7 million accrual for future lease payments.
• Inventory Valuation: Assess the remaining inventory levels and the potential for further write-downs given the depressed market prices for herbal products.
• Financing Availability: Monitor the renewal of the $3.0 million credit line expiring January 19, 2000, and the success of planned additional financing for fiscal 2000.
• Regulatory Compliance: Review any new FDA regulations or enforcement actions that could impact product labeling or manufacturing standards.